News

Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, entered into a…
Read More...

ACADIA Pharmaceuticals Inc. announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for…
Read More...

EpiVax, Inc. a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate,…
Read More...

HitGen Inc. announced that the company has achieved a milestone in their strategic collaboration with Almirall to develop a novel class of drugs. The licensed compounds were identified…
Read More...

AbbVie and Harvard University announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel…
Read More...

Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company announced that it has entered into a strategic collaboration with Vir Biotechnology, a clinical-stage immunology…
Read More...

Catalent, Inc. announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19…
Read More...

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, announced today the signing of a…
Read More...

Bristol Myers Squibb and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic…
Read More...

Bio-Thera Solutions, Ltd. and BeiGene, Ltd. announced that the companies have executed a license, distribution, and supply agreement for China for Bio-Thera’s BAT1706, an…
Read More...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce targeted polyclonal antibodies, announced the dosing of the…
Read More...

 Renalytix AI plc announced a collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the…
Read More...

Sanofi and Principia Biopharma Inc. entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100  per share in cash, which…
Read More...

Boehringer Ingelheim announced that the first patient has enrolled in InPedILD, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and…
Read More...

QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with…
Read More...

Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, announced the signing of a licensing agreement with Roche providing Celleron exclusive…
Read More...

GeneCentric Therapeutics announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for…
Read More...

Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19…
Read More...

Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury (remdesivir), an investigational antiviral…
Read More...

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal…
Read More...